Key facts
- Caremo Biopharmaceutical’s last known valuation is $257.3M (Jun 2022).
- It has raised $44.8M; the latest was Early Stage VC in Aug 2025.
- Notable investors include Jolmo Investment, Bondshine Capital, Tsing Song Capital, Zhejiang Shapuaisi Pharmaceutical Company.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Caremo Biopharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Caremo Biopharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Caremo Biopharmaceutical
Provider of biopharmaceutical and pharmaceutical clinical trial services designed for pharmaceutical companies. The company specailises in preclinical research, CMC development, clinical trial management, dosage form engineering, drug incubation support, laboratory testing and formulation optimisation, thereby accelerating drug discovery and improving development efficiency across the pharmaceutical lifecycle.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2020
- Employees
- 400
- Website
- caremo.com.cn/
- Ownership
- Privately Held (backing)
Caremo Biopharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Caremo Biopharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Caremo Biopharmaceutical in its N-PORT filings yet. We sweep new filings monthly.